Clinical Trial Update: Preoperative Intravitreal Ranibizumab for Persistent Diabetic Vitreous Haemorrhage: [Phase 2, Phase 3]

View source ↗

Summary

Update on a Phase 2/Phase 3 trial evaluating preoperative intravitreal ranibizumab for persistent diabetic vitreous haemorrhage.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Retinopathy

Drugs mentioned

• Lucentis (ranibizumab) (ranibizumab)

Snippet

Sponsor: King's College Hospital NHS Trust | Conditions: Diabetes Complications | Phase 2, Phase 3 | Status: COMPLETED